58584-92-2

Basic information

• Product Name: 2-Amino-5-chloropyridine-3-carboxylic acid
• Synonyms: 2-Amino-6-chloropyridine-3-carboxylicacid;2-Amino-6-chloronicotinic...;3-Pyridinecarboxylic acid, 2-aMino-6-chloro-;2-Amino-6-chloro-3-pyridinecarboxylic acid
• CAS NO: 58584-92-2
• Molecular Formula: C₆H₅ClN₂O₂
• Molecular Weight: 172.57
• Mol File: 58584-92-2.mol
• Article Data: 22

Chemical Properties

• Melting Point: 195-197°(dec)
• Boiling Point: 383.321 °C at 760 mmHg
• Flash Point: 185.626 °C
• Appearance: /
• Density: 1.577±0.06 g/cm3 (20 ºC 760 Torr)
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: 3.98±0.10(Predicted)
• CAS DataBase Reference: 2-Amino-5-chloropyridine-3-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Amino-5-chloropyridine-3-carboxylic acid(58584-92-2)
• EPA Substance Registry System: 2-Amino-5-chloropyridine-3-carboxylic acid(58584-92-2)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 58584-92-2(Hazardous Substances Data)

Usage

General Description

2-Amino-5-chloropyridine-3-carboxylic acid is a chemical compound with the molecular formula C6H5ClN2O2. It is a derivative of pyridine and contains both an amino group and a carboxylic acid group. 2-Amino-5-chloropyridine-3-carboxylic acid is primarily used as a building block or intermediate in the synthesis of pharmaceuticals and agrochemicals. It is known for its ability to form strong bonds with proteins and enzymes, making it a valuable tool in drug discovery and development. Additionally, it has shown potential as a corrosion inhibitor in industrial applications. Overall, 2-Amino-5-chloropyridine-3-carboxylic acid plays a crucial role in various chemical and biological processes.

Upstream product

• 849805-25-0 methyl 2-amino-6-chloropyridine-3-carboxylate 
• 64-17-5 ethanol 
• 52471-07-5 2-amino-6-chloro-3-cyanopyridine 
• 38496-18-3 2,6-dichloropyridine-3-carboxylic acid 
• 60-35-5 acetamide 

Downstream Products

• 849805-55-6 2-amino-N-(4-(benzyloxy)benzyl)-6-chloronicotinamide 
• 849805-25-0 methyl 2-amino-6-chloropyridine-3-carboxylate 
• 64321-24-0 2-amino-6-chloro-pyridine-3-carboxamide 
• 1005490-20-9 C₁₂H₉ClFN₃O 
• 58584-60-4 (2-amino-6-chloro-pyridin-3-yl)-methanol 
• 1391062-87-5 2-amino-6-chloronicotinic acid N-oxide 
• 938440-64-3 KU-63794 
• 1009302-61-7 C₂₄H₂₉N₅O₄ 
• 1009302-80-0 C₂₅H₃₂N₆O₃ 
• 1009302-46-8 C₂₄H₃₁N₅O₄ 
• 1009302-47-9 C₂₃H₂₄N₆O₃ 
• 1009298-09-2 AZD₈₀₅₅ 
• 938443-20-0 2,4,7-trichloropyrido[2,3-d]pyrimidine 
• 938443-21-1 4-(2,7-dichloropyrido[2,3-d]pyrimidin-4-yl)morpholine 

Relevant articles and documents

HETEROCYCLIC COMPOUNDS AS MTOR INHIBITORS

The present disclosure describes novel heterocyclic mTOR inhibitors and methods for preparing them. The pharmaceutical compositions comprising such mTOR inhibitors and methods of using them for treating cancer, infectious diseases, and other mTOR associated disorders are also described.

HETEROARYL COMPOUNDS AND THEIR USE AS THERAPEUTIC DRUGS

The present invention provides heterocyclic compounds, the stereoisomer thereof, the enantiomer thereof, or the pharmaceutically acceptable salt, which are capable of modulating the activity of Mer receptor tyrosine kinase (MERTK). This invention also provides pharmaceutical compositions thereof, methods to prepare the said compounds, and the use of such compounds as a medicament. The present invention is directed to MERTK inhibitory compounds with marked potency, thereby having an outstanding potential for a pharmaceutical intervention of cancer and any other diseases related to MERTK dysregulation.

Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: The discovery of AZD8055 and AZD2014

The optimization of a potent and highly selective series of dual mTORC1 and mTORC2 inhibitors is described. An initial focus on improving cellular potency whilst maintaining or improving other key parameters, such as aqueous solubility and margins over hERG IC50, led to the discovery of the clinical candidate AZD8055 (14). Further optimization, particularly aimed at reducing the rate of metabolism in human hepatocyte incubations, resulted in the discovery of the clinical candidate AZD2014 (21).